Navigation Links
MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen

Data published today in the Journal of the National Cancer Institute

BASEL, Switzerland, 2 May 2007 - In a study published today in the Journal of the National Cancer Institute, the innovative cancer drug MabThera was shown to improve overall survival in patients with lymphoma regardless of the chemotherapy regimen used.1 The review further stated that the improvement in survival was seen for the first time in patients with mantle cell lymphoma, a rare, aggressive form of lymphoma.

The study was a comprehensive, systematic meta-analysis review of newly-diagnosed or relapsed patients involved in trials that compared MabThera treatment regimens with chemotherapy alone. The review not only demonstrated improved overall survival with MabThera but also that disease control in the MabThera containing arms of the trials was significantly superior to chemotherapy alone.

"This meta analysis clearly demonstrates the contribution MabThera makes to the management of patients with indolent lymphoma," commented Prof. Andreas Engert, from the Cochrane Hematological Malignacies Group, University of Cologne, and one of the authors of the study. "The results confirm the addition of MabThera to treatment of patients with two major forms of NHL extends patients' lives, regardless of their chemotherapy regimen."

Non-Hodgkin's lymphoma (NHL) affects 1 million people worldwide. It is estimated that 360,000 people die each year from the disease.2 Indolent NHL, representing about 45% of NHL patients, is a slow developing but serious cancer of the lymphatic system.

About the study The study included only randomized controlled trials (RCT) comparing R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed indolent lymphoma and mantle cell lymphoma (MCL). Medical databases (Cochrane Library, MEDLINE, EMBA
'"/>




Page: 1 2 3 4

Related medicine technology :

1. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
2. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... -- Cepheid (NASDAQ: CPHD) announced today the release of ... test for rapid, accurate and reliable determination of ... infection. The test will be marketed as a ... In Vitro Diagnostic Medical Devices, bringing the ... XC runs on Cepheid,s GeneXpert ® System, ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4
(Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
(Date:9/2/2014)... is pleased to announce that the following papers ... the ESC Congress 2014, taking place in Barcelona, ... Ultrathin strut biodegradable polymer sirolimus-eluting stent versus ... (BIOSCIENCE): a randomised, single-blind, non-inferiority trial, Windecker et ... strut thickness, surface polymer, and drug release have ...
(Date:9/2/2014)... Researchers in New Delhi, India have published a ... exposed to asbestos-contaminated work clothes for just 3 months as ... report in a new article. Click here to read ... say their patient was diagnosed with mesothelioma after ... she had come in contact with her miner father’s dirty ...
(Date:9/2/2014)... Headaches, both chronic and acute ruin lives. ... family and friends, sleeping and just coping well with daily ... of disability worldwide. The medications prescribed for these conditions ... of these cases of headache and back pain are of ... will not detect and fix the cause. , When ...
(Date:9/2/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... Hospital in Sioux Falls, S.D. The top executive ... has recently placed more than 900 healthcare executives into ... physician-owned healthcare provider and nationally recognized leader in patient-centered ...
Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Physical Therapists in Houston Learn Pain Relief Techniques 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3
... from the Journal of Traumatic Stress finds ... who are happily married, communicating frequently with one,s spouse ... the development of posttraumatic stress disorder (PTSD) symptoms after ... male Army soldiers who returned from military deployment within ...
... (BUSM) researchers have found that Gabapentin, (trade name Neurontin) ... and biopolar disease in older and elderly patients, seems ... to experience orgasm, than previously reported. This study ... Journal of Geriatric Pharmacotherapy . Anticonvulsants are the ...
... , THURSDAY, June 2 (HealthDay News) -- People ... hospitalization are more than twice as likely to be readmitted ... a new study has found. The finding suggests that ... patients, according to the researchers, who were to present the ...
... , THURSDAY, June 2 (HealthDay News) -- Noisy operating ... site infections, new study findings suggest. In the ... Journal of Surgery , the Swiss researchers also said these ... costly hospital stays. "SSIs lead to patients spending up ...
... an investigational vaccine made from their own frozen immune ... with it, according to data being presented by researchers ... 2011 American Society of Clinical Oncology annual meeting in ... In an exploratory, multi-institutional analysis, researchers administered the ...
... By Kathleen Doheny HealthDay Reporter , ... that low-carbohydrate diets, with regular exercise as part of ... some experts have feared. "It,s pretty clear low-carb ... J. Stewart, director of clinical and research exercise physiology ...
Cached Medicine News:Health News:Letters from home may help prevent post-traumatic stress disorder in happily married soldiers 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:Noisy ORs Linked to Raised Risk of Surgical Site Infection 2Health News:ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 3
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Medicine Products: